Abstract
An improved overall survival (OS) and progression-free survival (PFS) were observed in patients with high body mass index (BMI) after receiving immune checkpoint inhibitor (ICI) treatment compared with patients of low BMI. No significant association between BMI and the incidence of immune-related adverse events (IRAEs) was found in cancer patients after ICI treatment.
Introduction: The Obesity Paradox in Oncology
Immune checkpoint inhibitors (ICIs), such as nivolumab and pembrolizumab, have revolutionized cancer care by enabling the immune system to recognize and eliminate malignant cells. Despite their success, clinical responses vary widely among patients. Researchers are actively seeking biomarkers—such as PD-L1 expression or tumor mutation burden—to predict which patients will benefit most from these therapies.
While obesity is a well-established risk factor for the development of various cancers, recent observations have suggested a counterintuitive "obesity paradox": heavier patients may actually exhibit superior responses to immunotherapy. This systematic review and meta-analysis aims to clarify the relationship between BMI and the efficacy and safety of ICIs.
Methods and Study Selection
The researchers performed a comprehensive search of major medical databases, including PubMed and EMBASE, through January 2020. The study focused on clinical trials and observational studies of solid tumors treated with ICIs where patient BMI data was recorded.
Data synthesis involved calculating pooled Hazard Ratios (HR) for Overall Survival (OS) and Progression-Free Survival (PFS), where an HR < 1.0 indicates a benefit for the high-BMI group. Relative Risk (RR) was used to assess the incidence of immune-related adverse events (IRAEs). The quality of the included studies was rigorously evaluated using the Newcastle-Ottawa Scale (NOS).
Datasets and Patient Characteristics
The final meta-analysis aggregated data from 13 eligible studies, encompassing a total of 5,279 patients. The cohort was geographically diverse, with participants from the USA, Canada, Europe, and Asia. Non-small cell lung cancer (NSCLC) was the most common malignancy (68.2%), followed by melanoma (18.5%) and renal cell carcinoma (10.2%). The majority of patients were treated with anti-PD-1 or anti-PD-L1 agents.
The Biological Basis for Improved Response
The observed benefit in high-BMI patients may be driven by several biological mechanisms:
- T-Cell Sensitivity: Obesity is associated with an increase in aged T cells that express high levels of PD-1. While these cells are often "exhausted," they are highly sensitive to reactivation by ICIs.
- Meta-inflammation: Chronic low-grade inflammation associated with adipose tissue (meta-inflammation) may paradoxically prime the immune system, enhancing the anti-tumor activity triggered by immunotherapy.
Key Results: Survival and Safety
The meta-analysis revealed a significant survival advantage for patients with high BMI. The pooled HR for Overall Survival was 0.62 (95% CI 0.55–0.71), representing a 38% reduction in the risk of death compared to the low-BMI group. Similarly, high BMI was associated with improved Progression-Free Survival (HR = 0.71; 95% CI 0.61–0.83).
Importantly, this increased efficacy did not come at the cost of higher toxicity. There was no statistically significant difference in the incidence of "all-grade" IRAEs between overweight or obese patients and those with a normal BMI.
Discussion and Limitations
While the findings are compelling, several limitations must be considered. All included studies were retrospective, which introduces potential selection bias. Furthermore, BMI is a relatively crude measure that does not differentiate between adipose tissue and lean muscle mass. Future research should utilize more precise body composition metrics, such as CT-based measurements of visceral fat and skeletal muscle.
Additionally, the "obesity paradox" may be partially explained by "cancer cachexia"—a wasting syndrome common in advanced cancer. Patients with a low BMI may simply be sicker at the start of treatment, making high BMI appear protective by comparison. Further prospective trials are needed to untangle these metabolic and clinical variables.
Summary updated